Safety and efficacy of continuous serratus anterior block in thoracoscopic surgery

Safety and Effectiveness of Ropivacaine in Continuous Serratus Anterior Plane Block in Video-Assisted Thoracoscopic Surgery

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100053517

Enrollment

Unknown

Registered

2021-11-24

Start date

2021-11-21

Completion date

Unknown

Last updated

2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Low-concentration ropivacaine SAPB group:Give low-level ropivacaine

High-concentration ropivacaine SAPB group:Give high-level ropivacaine

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. American Society of Anesthesiologists (American Society of Anesthesiologists physical status, ASA) classification I-III; 2. Aged 18-70 years; 3. Body Mass Index (BMI) 18-30 kg/m^2; 4. Elective first thoracoscopic surgery; 5. Clear awareness, good communication, informed about the experiment, and voluntarily signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Severe coagulation dysfunction; 2. Whole body or puncture site infection; 3. Allergies to the research drug and contraindications; 4. Severe renal and cardiac damage (New York Heart Association classes III-IV); 5. There is a history of chronic pain or persistent pain due to other diseases, and there is analgesic treatment before surgery.

Design outcomes

Primary

Measure	Time frame
visual analogue scale;	—

Secondary

Measure	Time frame
blood concentration;	—

Countries

China

Contacts

Public ContactWang Di

The First Affiliated Hospital of University of Science and Technology of China

di.wang@ustc.edu.cn+86 13515604532

Outcome results